Telix Pharmaceuticals (ASX:TLX) has announced that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland (UQ).
The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science.
The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry.
According to Telix chief scientist Dr Michael Wheatcroft, “Key to the development of personalised therapy is reliable and scalable manufacture of new products, harnessing emerging technological innovations in the field. This grant will enable the establishment of AMTAR, a unique opportunity to further University of Queensland and Telix’s research and development collaboration, and capitalise on the biologics expertise of UQ and the Australian Institute for Bioengineering and Nanotechnology (AIBN) to work with new antibodies, chelators and bioconjugation processes in the development of novel radiopharmaceutical candidates. We would like to thank Professor Kristofer Thurecht and his team at The University of Queensland for leading a successful application and the Australian Research Council for funding.”
AMTAR Research Hub director Professor Kristofer Thurecht from The University of Queensland added, “We are pleased to be working with Telix and other industry and academic partners on this exciting and innovative research program. A key member of a high calibre project team, Telix’s deep expertise in biologics as radiopharmaceuticals will help drive clinical and commercial translation, and advance the technologies required to ensure long-term production capability in Australia.”